The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy

Aniruddha Agarwal, Sally A. Ingham, Keegan A. Harkins, DIana V. Do, Quan Dong Nguyen

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Diabetic retinopathy (DR) and its complications such as diabetic macular edema continue to remain a major cause for legal blindness in the developed world. While the introduction of anti-tVEGF agents has significantly improved visual outcomes of patients with DR, unpredictable response, largely due to genetic polymorphisms, appears to be a challenge with this therapy. With advances in identification of various genetic biomarkers, novel therapeutic strategies consisting of gene transfer are being developed and tested for patients with DR. Application of pharmacogenetic principles appears to be a promising futuristic strategy to attenuate diabetes-mediated retinal vasculopathy. In this comprehensive review, data from recent studies in the field of pharmacogenomics for the treatment of DR have been provided.

Original languageEnglish (US)
Pages (from-to)309-320
Number of pages12
JournalPharmacogenomics
Volume17
Issue number3
DOIs
StatePublished - Feb 2016

Fingerprint

Pharmacogenetics
Diabetic Retinopathy
Genetic Therapy
Macular Edema
Genetic Polymorphisms
Blindness
Therapeutics
Biomarkers
Genes

Keywords

  • HLA
  • VEGF mutation
  • diabetic retinopathy
  • gene therapy
  • genomic markers
  • linkage
  • mutation
  • pharmacogenomics
  • polymorphism
  • viral vectors

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Agarwal, A., Ingham, S. A., Harkins, K. A., Do, DI. V., & Nguyen, Q. D. (2016). The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy. Pharmacogenomics, 17(3), 309-320. https://doi.org/10.2217/pgs.15.173

The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy. / Agarwal, Aniruddha; Ingham, Sally A.; Harkins, Keegan A.; Do, DIana V.; Nguyen, Quan Dong.

In: Pharmacogenomics, Vol. 17, No. 3, 02.2016, p. 309-320.

Research output: Contribution to journalReview article

Agarwal, A, Ingham, SA, Harkins, KA, Do, DIV & Nguyen, QD 2016, 'The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy', Pharmacogenomics, vol. 17, no. 3, pp. 309-320. https://doi.org/10.2217/pgs.15.173
Agarwal, Aniruddha ; Ingham, Sally A. ; Harkins, Keegan A. ; Do, DIana V. ; Nguyen, Quan Dong. / The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy. In: Pharmacogenomics. 2016 ; Vol. 17, No. 3. pp. 309-320.
@article{de793ce8b11f418c81f396e103086fa5,
title = "The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy",
abstract = "Diabetic retinopathy (DR) and its complications such as diabetic macular edema continue to remain a major cause for legal blindness in the developed world. While the introduction of anti-tVEGF agents has significantly improved visual outcomes of patients with DR, unpredictable response, largely due to genetic polymorphisms, appears to be a challenge with this therapy. With advances in identification of various genetic biomarkers, novel therapeutic strategies consisting of gene transfer are being developed and tested for patients with DR. Application of pharmacogenetic principles appears to be a promising futuristic strategy to attenuate diabetes-mediated retinal vasculopathy. In this comprehensive review, data from recent studies in the field of pharmacogenomics for the treatment of DR have been provided.",
keywords = "HLA, VEGF mutation, diabetic retinopathy, gene therapy, genomic markers, linkage, mutation, pharmacogenomics, polymorphism, viral vectors",
author = "Aniruddha Agarwal and Ingham, {Sally A.} and Harkins, {Keegan A.} and Do, {DIana V.} and Nguyen, {Quan Dong}",
year = "2016",
month = "2",
doi = "10.2217/pgs.15.173",
language = "English (US)",
volume = "17",
pages = "309--320",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy

AU - Agarwal, Aniruddha

AU - Ingham, Sally A.

AU - Harkins, Keegan A.

AU - Do, DIana V.

AU - Nguyen, Quan Dong

PY - 2016/2

Y1 - 2016/2

N2 - Diabetic retinopathy (DR) and its complications such as diabetic macular edema continue to remain a major cause for legal blindness in the developed world. While the introduction of anti-tVEGF agents has significantly improved visual outcomes of patients with DR, unpredictable response, largely due to genetic polymorphisms, appears to be a challenge with this therapy. With advances in identification of various genetic biomarkers, novel therapeutic strategies consisting of gene transfer are being developed and tested for patients with DR. Application of pharmacogenetic principles appears to be a promising futuristic strategy to attenuate diabetes-mediated retinal vasculopathy. In this comprehensive review, data from recent studies in the field of pharmacogenomics for the treatment of DR have been provided.

AB - Diabetic retinopathy (DR) and its complications such as diabetic macular edema continue to remain a major cause for legal blindness in the developed world. While the introduction of anti-tVEGF agents has significantly improved visual outcomes of patients with DR, unpredictable response, largely due to genetic polymorphisms, appears to be a challenge with this therapy. With advances in identification of various genetic biomarkers, novel therapeutic strategies consisting of gene transfer are being developed and tested for patients with DR. Application of pharmacogenetic principles appears to be a promising futuristic strategy to attenuate diabetes-mediated retinal vasculopathy. In this comprehensive review, data from recent studies in the field of pharmacogenomics for the treatment of DR have been provided.

KW - HLA

KW - VEGF mutation

KW - diabetic retinopathy

KW - gene therapy

KW - genomic markers

KW - linkage

KW - mutation

KW - pharmacogenomics

KW - polymorphism

KW - viral vectors

UR - http://www.scopus.com/inward/record.url?scp=84956630737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956630737&partnerID=8YFLogxK

U2 - 10.2217/pgs.15.173

DO - 10.2217/pgs.15.173

M3 - Review article

C2 - 26807609

AN - SCOPUS:84956630737

VL - 17

SP - 309

EP - 320

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 3

ER -